Alphabet has created a new owned company called Isomorphic Labs that will focus on using AI processes to develop new drugs.
Sprouting from Deepmind, another subsidiary of AI Alphabet, the idea of Isomorphic Labs came after Deepmind AI’s AlphaFold 2 program solved a 50-year challenge of protein wrapping by predicting 3D protein formation directly from sequence its amino acid to the atomic level accuracy.
Following this success, Deepmind founder and Isomorphic Labs and CEO, Demis Hassabis said he now believes AI techniques and methods are powerful and complex enough to be applied to real-world problems, including the discovery of science itself. During the first phase of Isomorphic Lab operations, Hassabis will be its CEO to help facilitate the partnership between the new subsidiary and Deepmind.
Read More: zdnet
